AzTrials
AzTrials

Arthritis KneeALGGARNCT03850392

Anti Inflammatory Effects of Local Cryotherapy in Knee Arthritis

A study testing cryotherapy (Thermogel - Artsana or Cryo+ - Cryonic) in people with Arthritis Knee and Cryotherapy Effect, run by Centre Hospitalier Universitaire de Besancon.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

47 patients with non-septic knee arthritis were treated by local ice (30 min) or cold CO2 (2 min) twice at an 8 hour-interval for 1 day. The synovial fluid was collected just before the first cold application then 24 hours later. Read more about this study

Who is it for?
Ages Up to 85 years
Conditions the study is for
Arthritis Knee, Cryotherapy Effect
What is being tested?
cryotherapy (Thermogel - Artsana or Cryo+ - Cryonic)
Could I receive a placebo?
No, everyone receives an active treatment
How many people
47 participants
Where
No sites listed yet
Study dates
12 Feb 2013to 22 Jun 2017
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Up to 85 years
  • All sexes
  • No healthy volunteers
  • Child, Adult, Older adult

Who may be able to join

  • non-septic knee arthritis

Who cannot join

  • biologic treatment within the last 6 months, septic arthritis

About this study

Official title: Effects of Local Cryotherapy on Cytokine, VRGF, NFkB and PG-E2 Levels in Knee Arthritis

47 patients with non-septic knee arthritis were treated by local ice (30 min) or cold CO2 (2 min) twice at an 8 hour-interval for 1 day.

The synovial fluid was collected just before the first cold application then 24 hours later.

Cytokine, VEGF, NF-kB, PG-E2 levels were assessed in the synovial fluid before/after treatment.

Contralateral arthritic knees were used as paired controls when possible.

Read the detailed description

Patient inclusion Patients hospitalized in the rheumatology department in the Besançon university hospital in France and suffering from non-septic knee arthritis (rheumatoid arthritis according to the ACR-EULAR criteria, spondyloarthritis according to the ASAS criteria, gout or calcium pyrophosphate deposition disease (CPDD) - diagnosed by microscopic microcrystal assessment in synovial fluid) were included consecutively after signed informed consent. The protocol was declared and approved by the local ethic committee - clinicaltrials.gov:NCT02573298, Comité de Protection des Personnes - Est II: 12-664) and all research was performed in accordance with relevant guidelines/regulations. Patients suffering from septic arthritides and knee osteoarthritis were excluded. The patients had received no biologic treatment nor conventional DMARD for the 6 months preceding inclusion. Corticosteroids, colchicine and NSAIDs were stopped for at least 24 hours prior to inclusion.

Study design In the first phase of the study, the included patients were then randomized (1:1) to receive either local ice (Thermogel®, Artsana, Grandate, Italy - 30 minutes application - N=16) or hyperbaric cold CO2 at -78°C (Cryo+®, Cryonic, Salins-les-Bains, France - 2 minutes-N=16). Each patient received two applications of the randomly chosen technique at an 8 hour interval (9 a.m and 5 p.m). The skin temperature was monitored on the treated knee using MLT409/A Skin Temperature Probe® and ML309 Thermistor Pod® (ADInstruments,Dunedin, NZ). Thirty of these 32 patients were also included in another part of the study,aiming at evaluating the variations of the synovial power Doppler semi-quantitative score before/after 2 cold applications (ice versus cold CO2) 2. Just before the first cold application, at 9 a.m., and 24 hours later (day=1 at 9 a.m), an arthrocentesis was performed. Standard analyses were performed on the synovial fluid (bacteriology, cytology and microcrystal microscopic assessment). Furthermore, a part of the synovial fluid was centrifuged then frozen at -80°C. For the second arthrocentesis, after the synovial fluid was gathered for the same analyses, an intra-joint corticosteroid injection (Triamcinolone, HEXATRIONE®, Ethypharm, Saint-Cloud, France) was performed before removing the needle. These synovial fluid samples were used to perform the present part of the study, which was overall powered to evaluate the IL-6 level variations in the synovial fluid before/after 2 cold applications. After all the patients were included, synovial fluid IL-6, IL-17A, IL-1β, TNF-α, VEGF (Multiplex flow cytometry, CBA® BD Bioscience, Franklin Lakes, New Jersey, USA) and PG-E2 (ELISA, KGE004B®, Bio-Techne, Minneapolis, Minnesota, USA), NF-KB-P65/NFkB- p65-P (ELISA,85-86083-11®, Thermofisher, Waltham, Massachusetts, USA) levels were measured.

In the second phase of the study, we only included patients suffering from arthritides of both knees and treated them with local ice only, according to the protocol described above (N=15 +1 patient with knee bi-arthritis previously included in the first phase of the study in the ice treated group). The same protocol was applied to contralateral non-treated knees except cryotherapy treatment. Therefore, the synovial fluid was gathered and analyzed at the same evaluation times compared to treated knees, so these contralateral arthritic knees were used as paired controls for cytokine and enzyme assays (N=16).

Statistical analyses. The sample size was calculated in order to detect a significant variation in IL-6 synovialprotein levels before/after 2 cold applications. 15.78 (N=16) patients per group were necessary to detect a difference of 2325 pg/mL in IL-6 protein level with a power of 95% and a p-value of 0.05, according to published results of IL-6 assays in knee synovial fluid. Therefore, 2 groups of 16 patients were included in the first randomized phase of the study(ice versus cold CO2), then 16 patients with knee bi-arthritis were required for the second phase of the study (ice-treated versus contralateral knee, N=15+1 patient already enrolled in the first phase). For these reasons, a total of 47 patients were included. Paired Wilcoxon Mann-Whitney tests were performed in order to compare the mean cytokine and enzyme levels before/after treatment. Subgroup analyses were also planned (according to the treatment modalities (ice or cold CO2) and to the type of rheumatic disease (microcrystalinduced arthritides - pooled gout and CPDD patients - versus non-microcrystal-induced diseases - pooled RA and SpA patients). Furthermore, an interclass effect-size (weighted mean differences with 95% CI) for cytokine levels (before/after treatment) was calculated between ice-treated knees and the corresponding contralateral non-treated knees using R® software (rmeta® and meta® packages). Correlation tests were also performed using Pearson's coefficients in order to assess the parameters associated with cytokine level variations (before/after treatment). The statistical analyses were performed using R® and Graphpad® softwares.

Additional informations Funding: This work was supported by GIRCI Est II ("Young scientist" grant - 2014 - 21324 euros).

Competing interests: None.

Being tested
cryotherapy (Thermogel - Artsana or Cryo+ - Cryonic)
Keywords
cryotherapy, knee arthritis, cytokines

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • cryotherapy (Thermogel - Artsana or Cryo+ - Cryonic)Device

    cold application (ice 30 min or cold CO2 2 min) twice during 1 day at an 8 hour-interval

Study groups in NCT03850392
Study groupRoleWhat they receive
iceActive comparator16 knee arthritis patients treated by local ice (Thermogel®, Artsana, Grandate, Italy - 30 minutes application - twice within one single day). Just before the first cold application, at 9 a.m., and 24 hours later (day=1 at 9 a.m), an arthrocentesis was performed. Standard analyses were performed on the synovial fluid (bacteriology, cytology and microcrystal microscopic assessment). Furthermore, a part of the synovial fluid was centrifuged then frozen at -80°C. For the second arthrocentesis, after the synovial fluid was gathered for the same analyses, an intra-joint corticosteroid injection (Triamcinolone, HEXATRIONE®,Ethypharm, Saint-Cloud, France) was performed before removing the needle.
Receives: Device: cryotherapy (Thermogel - Artsana or Cryo+ - Cryonic)
CO2Active comparator16 knee arthritis patients treated by local hyperbaric cold CO2 at -78°C (Cryo+®, Cryonic, Salins-les-Bains, France - 2 minutes-applied twice within one single day). Just before the first cold application, at 9 a.m., and 24 hours later (day=1 at 9 a.m), an arthrocentesis was performed. Standard analyses were performed on the synovial fluid (bacteriology, cytology and microcrystal microscopic assessment). Furthermore, a part of the synovial fluid was centrifuged then frozen at -80°C. For the second arthrocentesis, after the synovial fluid was gathered for the same analyses, an intra-joint corticosteroid injection (Triamcinolone, HEXATRIONE®, Ethypharm, Saint-Cloud, France) was performed before removing the needle.
Receives: Device: cryotherapy (Thermogel - Artsana or Cryo+ - Cryonic)
contralateral non-treated kneesNo intervention16 contralateral arthritic knees : the synovial fluid was collected and analysed according to the same procedure but no cold treatment was applied (while the corresponding contralateral arthritic knees were treated by ice) : At 9 a.m., and 24 hours later (day=1 at 9 a.m), an arthrocentesis was performed. Standard analyses were performed on the synovial fluid (bacteriology, cytology and microcrystal microscopic assessment). Furthermore, a part of the synovial fluid was centrifuged then frozen at -80°C. For the second arthrocentesis, after the synovial fluid was gathered for the same analyses, an intra-joint corticosteroid injection (Triamcinolone, HEXATRIONE®,Ethypharm, Saint-Cloud, France) was performed before removing the needle.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Il-6 protein level change in the synovial fluid (before / after treatment)

    Multiplex cytometry technique (pg/mL)

    Measured: just before treatment (9 a.m) then 24 hours later (variation)

Secondary outcomes (8)
  1. pain Visual Analogic Scale change before / after treatment

    0 (minimum) -10 (maximum) numeric scale (0 : better - 10 : worse)

    Measured: just before treatment (9 a.m) then 24 hours later (variation)

  2. TNF-alpha change in the synovial fluid

    Multiplex cytometry (pg/mL)

    Measured: just before treatment (9 a.m) then 24 hours later (variation)

  3. IL-1 beta change in the synovial fluid

    Multiplex cytometry (pg/mL)

    Measured: just before treatment (9 a.m) then 24 hours later (variation)

  4. IL-17A change in the synovial fluid

    Multiplex cytometry (pg/mL)

    Measured: just before treatment (9 a.m) then 24 hours later (variation)

  5. VEGF change in the synovial fluid

    Multiplex cytometry (pg/mL)

    Measured: just before treatment (9 a.m) then 24 hours later (variation)

  6. NF-kB-p65 change in the synovial fluid

    ELISA (optical density)

    Measured: just before treatment (9 a.m) then 24 hours later (variation)

  7. phosphorylated NF-kB-p65 change in the synovial fluid

    ELISA (optical density)

    Measured: just before treatment (9 a.m) then 24 hours later (variation)

  8. PG-E2 change in the synovial fluid

    ELISA (optical density)

    Measured: just before treatment (9 a.m) then 24 hours later (variation)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted21 Feb 2019
  2. Study start12 Feb 2013
  3. Primary completion8 Mar 2017
  4. Study completion22 Jun 2017

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Sequential
Model description
first phase : randomization ice versus cold CO2 second phase : ice-treated knees versus contralateral non-treated knees
Masking
Single blind
Who is masked
Outcomes assessor
Enrolment
47 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03850392
Sponsor's protocol ID
2012-A00848-35
Acronym
ALGGAR
Status last verified
Feb 2019
First submitted
18 Feb 2019
Last updated
21 Feb 2019
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Guillot X, Tordi N, Laheurte C, Pazart L, Prati C, Saas P, Wendling D. Local ice cryotherapy decreases synovial interleukin 6, interleukin 1beta, vascular endothelial growth factor, prostaglandin-E2, and nuclear factor kappa B p65 in human knee arthritis: a controlled study. Arthritis Res Ther. 2019 Jul 30;21(1):180. doi: 10.1186/s13075-019-1965-0.

    PubMed 31362785

Questions about this trial

What is this clinical trial studying?

A study testing cryotherapy (Thermogel - Artsana or Cryo+ - Cryonic) in people with Arthritis Knee and Cryotherapy Effect, run by Centre Hospitalier Universitaire de Besancon.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 21 Feb 2019. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Il-6 protein level change in the synovial fluid (before / after treatment) (time frame: just before treatment (9 a.m) then 24 hours later (variation)). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03850392, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Feb 2019.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in